WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response

Szymon Janczar(Hammersmith Hospital), Hani Gabra(Royal Children's Hospital)

Cell Death and Disease

July 27, 2017

10.1038/cddis.2017.346

Cited by 35

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes

|Nature reviews. Cancer|2011|1.5k

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

|Cancer Research|2011|179

PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

|Clinical Cancer Research|2009|166